Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:AFMDNASDAQ:EYENNASDAQ:FGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.44-2.0%$1.32$1.05▼$5.17$159.17M0.411.20 million shs605,826 shsAFMDAffimed$0.18-34.9%$0.48$0.07▼$7.11$2.92M2.074.36 million shs22.99 million shsEYENEyenovia$2.97+21.7%$1.64$0.85▼$124.80$8.56M1763,682 shs1.20 million shsFGENFibroGen$0.27+0.8%$0.31$4.50▼$38.25$26.67M0.8378,545 shs1.00 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-3.92%+12.21%-6.96%+24.58%AFMDAffimed0.00%0.00%-34.95%-79.81%-97.44%EYENEyenovia0.00%-50.00%+115.93%+42.69%-95.17%FGENFibroGen0.00%-15.77%-13.76%-40.70%-76.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.6219 of 5 stars3.61.00.00.03.01.71.3AFMDAffimed2.7921 of 5 stars4.00.00.04.30.60.01.3EYENEyenovia0.466 of 5 stars1.02.00.00.01.90.01.3FGENFibroGen4.561 of 5 stars3.35.00.04.71.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$9.71574.60% UpsideAFMDAffimed 2.00Hold$3.621,895.87% UpsideEYENEyenovia 2.00Hold$2.00-32.66% DownsideFGENFibroGen 2.50Moderate Buy$10.003,657.99% UpsideCurrent Analyst Ratings BreakdownLatest AFMD, FGEN, EYEN, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/14/2025AFMDAffimedCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025AFMDAffimedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/13/2025AFMDAffimedLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025AFMDAffimedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.105/13/2025AFMDAffimedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.395/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.004/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/21/2025EYENEyenoviaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$17.78M8.77N/AN/A$2.22 per share0.65AFMDAffimed$877K3.33N/AN/A$4.19 per share0.04EYENEyenovia$67.06K127.68N/AN/A$16.32 per share0.18FGENFibroGen$7.00M3.84N/AN/A($1.87) per share-0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.39N/AN/AN/A-136.65%-40.26%-31.71%8/6/2025 (Estimated)AFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)EYENEyenovia-$27.26M-$58.40N/AN/AN/A-114,639.41%-1,108.24%-139.36%8/11/2025 (Estimated)FGENFibroGen-$284.23M-$0.10N/AN/AN/A-67.66%N/A-36.17%8/5/2025 (Estimated)Latest AFMD, FGEN, EYEN, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/12/2025Q1 2025FGENFibroGen$0.03-$0.16-$0.19$0.05$2.00 million$2.70 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAFMDAffimedN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A7.037.03AFMDAffimed0.131.931.93EYENEyenovia0.580.740.55FGENFibroGenN/A1.281.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AFMDAffimed30.82%EYENEyenovia25.84%FGENFibroGen72.71%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%AFMDAffimed3.80%EYENEyenovia7.10%FGENFibroGen3.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million66.86 millionOptionableAFMDAffimed20016.10 million15.49 millionOptionableEYENEyenovia402.88 million1.29 millionOptionableFGENFibroGen570101.04 million98.78 millionOptionableAFMD, FGEN, EYEN, and ACRS HeadlinesRecent News About These CompaniesFibroGen To Implement 1-for-25 Reverse Stock SplitJune 14 at 4:43 PM | nasdaq.comFibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025June 14 at 4:43 PM | nasdaq.comFibroGen Enters Relicensing Agreement with HiFiBiOJune 14 at 12:21 AM | marketwatch.comFibroGen Announces 1-for-25 Reverse Stock SplitJune 12, 2025 | globenewswire.comFibroGen, Inc. Appoints Dr. Michael Kauffman to Board of DirectorsJune 9, 2025 | quiverquant.comFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of DirectorsJune 9, 2025 | globenewswire.comFibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipelineMay 13, 2025 | msn.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comFibroGen, Inc.: FibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deFibroGen, Inc. (FGEN) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comFibroGen (FGEN) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comFibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comA Preview Of FibroGen's EarningsMay 10, 2025 | benzinga.comDuchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)May 8, 2025 | globenewswire.comFibroGen, Inc. to Announce Q1 2025 Financial Results and Host Conference Call on May 12May 7, 2025 | nasdaq.comFibroGen to Report First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comWilliam Blair Keeps Their Hold Rating on FibroGen (FGEN)April 2, 2025 | markets.businessinsider.comFibroGen to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comFibroGen extends merger option deadline with FortisMarch 30, 2025 | investing.comFibroGen announces publication of results from Phase 1 study of FG-3246March 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAFMD, FGEN, EYEN, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.44 -0.03 (-2.04%) Closing price 04:00 PM EasternExtended Trading$1.42 -0.02 (-1.39%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Affimed NASDAQ:AFMD$0.18 -0.10 (-34.95%) As of 05/19/2025Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Eyenovia NASDAQ:EYEN$2.97 +0.53 (+21.72%) Closing price 04:00 PM EasternExtended Trading$2.91 -0.06 (-1.89%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.FibroGen NASDAQ:FGEN$0.27 +0.00 (+0.83%) Closing price 04:00 PM EasternExtended Trading$0.27 0.00 (-0.04%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
